Details
Stereochemistry | RACEMIC |
Molecular Formula | C23H26N2O2 |
Molecular Weight | 362.4647 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C1CCC(C2CCN(CC3=CC=CC=C3)CC2)(C(=O)N1)C4=CC=CC=C4
InChI
InChIKey=LQQIVYSCPWCSSD-UHFFFAOYSA-N
InChI=1S/C23H26N2O2/c26-21-11-14-23(22(27)24-21,19-9-5-2-6-10-19)20-12-15-25(16-13-20)17-18-7-3-1-4-8-18/h1-10,20H,11-17H2,(H,24,26,27)
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
The allosteric interaction of otenzepad (AF-DX 116) at muscarinic M2 receptors in guinea pig atria. | 2001 Mar 30 |
|
Labelling of the solvent DMSO as side reaction of methylations with n.c.a. [11C]CH3I. | 2001 Sep |
|
Variable effects of previously untested muscarinic receptor antagonists on experimental myopia. | 2003 Mar |
|
Sequential 123I-iododexetimide scans in temporal lobe epilepsy: comparison with neuroimaging scans (MR imaging and 18F-FDG PET imaging). | 2005 Feb |
|
Defects in muscarinic receptor-coupled signal transduction in isolated parotid gland cells after in vivo irradiation: evidence for a non-DNA target of radiation. | 2005 Feb 14 |
|
Reduced posterior cingulate binding of I-123 iodo-dexetimide to muscarinic receptors in mild Alzheimer's disease. | 2005 May |
|
Synthesis and structure-activity relationship of benzetimide derivatives as human CXCR3 antagonists. | 2008 Nov 1 |
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29704
Created by
admin on Fri Dec 15 16:08:39 GMT 2023 , Edited by admin on Fri Dec 15 16:08:39 GMT 2023
|
||
|
WHO-VATC |
QA03AB90
Created by
admin on Fri Dec 15 16:08:39 GMT 2023 , Edited by admin on Fri Dec 15 16:08:39 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
21847
Created by
admin on Fri Dec 15 16:08:39 GMT 2023 , Edited by admin on Fri Dec 15 16:08:39 GMT 2023
|
PRIMARY | |||
|
SUB05747MIG
Created by
admin on Fri Dec 15 16:08:39 GMT 2023 , Edited by admin on Fri Dec 15 16:08:39 GMT 2023
|
PRIMARY | |||
|
CHEMBL10272
Created by
admin on Fri Dec 15 16:08:39 GMT 2023 , Edited by admin on Fri Dec 15 16:08:39 GMT 2023
|
PRIMARY | |||
|
1708
Created by
admin on Fri Dec 15 16:08:39 GMT 2023 , Edited by admin on Fri Dec 15 16:08:39 GMT 2023
|
PRIMARY | |||
|
DTXSID2046173
Created by
admin on Fri Dec 15 16:08:39 GMT 2023 , Edited by admin on Fri Dec 15 16:08:39 GMT 2023
|
PRIMARY | |||
|
14051-33-3
Created by
admin on Fri Dec 15 16:08:39 GMT 2023 , Edited by admin on Fri Dec 15 16:08:39 GMT 2023
|
PRIMARY | |||
|
C73007
Created by
admin on Fri Dec 15 16:08:39 GMT 2023 , Edited by admin on Fri Dec 15 16:08:39 GMT 2023
|
PRIMARY | |||
|
m2347
Created by
admin on Fri Dec 15 16:08:39 GMT 2023 , Edited by admin on Fri Dec 15 16:08:39 GMT 2023
|
PRIMARY | Merck Index | ||
|
B987T0L5FX
Created by
admin on Fri Dec 15 16:08:39 GMT 2023 , Edited by admin on Fri Dec 15 16:08:39 GMT 2023
|
PRIMARY | |||
|
100000086383
Created by
admin on Fri Dec 15 16:08:39 GMT 2023 , Edited by admin on Fri Dec 15 16:08:39 GMT 2023
|
PRIMARY | |||
|
119391-55-8
Created by
admin on Fri Dec 15 16:08:39 GMT 2023 , Edited by admin on Fri Dec 15 16:08:39 GMT 2023
|
SUPERSEDED |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)